Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:39:17 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



Q:VSTM - VERASTEM INC - https://www.verastem.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VSTM - Q0.19.07·11.970.110.90+0.545.2104.31,0741,18010.48  11.16  10.4815.1861  4.681916:42:08Apr 1815 min RT 2¢

Recent Trades - Last 10 of 1180
Time ETExPriceChangeVolume
16:42:08Q10.69960.33961
16:00:00Q10.900.5410,161
16:00:00Q10.900.54227
16:00:00Q10.900.5478
16:00:00Q10.900.54700
16:00:00Q10.900.542
16:00:00Q10.900.5433
16:00:00Q10.900.547
16:00:00Q10.900.542,200
16:00:00Q10.900.5476

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 16:05U:VSTMNews ReleaseVerastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
2024-04-04 07:30U:VSTMNews ReleaseVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-18 07:00U:VSTMNews ReleaseGlobal Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
2024-03-14 16:05U:VSTMNews ReleaseVerastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
2024-03-11 07:30U:VSTMNews ReleaseVerastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
2024-03-05 17:27U:VSTMNews ReleaseVerastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
2024-03-05 16:30U:VSTMNews ReleaseVerastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
2024-01-29 07:00U:VSTMNews ReleaseVerastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
2024-01-18 16:00U:VSTMNews ReleaseVerastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
2024-01-11 07:00U:VSTMNews ReleaseVerastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
2024-01-05 07:00U:VSTMNews ReleaseVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-18 07:00U:VSTMNews ReleaseVerastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
2023-12-13 07:00U:VSTMNews ReleaseVerastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
2023-11-13 07:00U:VSTMNews ReleaseNew Healthcare Professional Component of Let ¢ € ™s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
2023-11-08 16:12U:VSTMNews ReleaseVerastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
2023-11-07 07:00U:VSTMNews ReleaseFirst-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer
2023-11-06 07:00U:VSTMNews ReleaseVerastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
2023-10-26 16:05U:VSTMNews ReleaseVerastem Oncology Strengthens Executive Leadership Team with Key Appointments
2023-10-18 16:50U:VSTMNews ReleaseVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-14 12:30U:VSTMNews ReleaseVerastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS ¢ „ ¢ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer